Tags

Type your tag names separated by a space and hit enter

Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy.
Oncotarget. 2016 Jun 14; 7(24):35618-35631.O

Abstract

Diabetic cardiomyopathy (DCM) is characterized by structural alterations such as cardiomyocyte hypertrophy, necrosis and focal fibrosis. Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear enzyme which can be activated by DNA damage and plays a critical role in various diseases. We hypothesized that PARP-1 may play an important role in DCM and that its inhibition may protect cardiomyocytes from inflammation and apoptosis in DCM. H9c2 cardiomyocytes were treated with normal glucose, mannitol or high glucose (HG). Male C57BL/6 mice or PARP-1-/- mice were treated with streptozotocin (STZ) by intraperitoneal injection for 5 consecutive days to induce diabetes. In vitro, HG stimulation induced oxidative stress and DNA damage and increased PARP-1 expression and activity. Compared with the control, pretreatment with PARP-1 siRNA signiï¬쎼cantly reduced HG-induced inflammatory response, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6 secretion, and intercellular adhesion molecule-1 (ICAM-1) and inducible nitric oxide synthase (iNOS) expression. PARP-1 inhibition reduced HG-induced cardiomyocyte apoptosis through downregulation of cleaved caspases and activation of IGF-1R/Akt pathway. In vivo, hyperglycemia increased the protein expression of nitrotyrosine and PARP-1 as well as PARP-1 activity. PARP-1 gene deletion significantly improved cardiac dysfunction and reduced inflammatory response and apoptosis. This work demonstrated the critical role of PARP-1 in diabetic heart injury, and suggested that PARP-1 inhibition may be a feasible strategy for the treatment of DCM.

Authors+Show Affiliations

Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.The Henan Provincial Key Engineering Laboratory of Antibody Drugs, School of Medicine, Henan University, Kaifeng, Henan, China.Department of Cardiology, The Second Hospital of Shandong University, Jinan, Shandong, China.Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.The Henan Provincial Key Engineering Laboratory of Antibody Drugs, School of Medicine, Henan University, Kaifeng, Henan, China.Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Qilu Hospital of Shandong University, Jinan, Shandong, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27027354

Citation

Qin, Wei-Dong, et al. "Poly(ADP-ribose) Polymerase 1 Inhibition Protects Cardiomyocytes From Inflammation and Apoptosis in Diabetic Cardiomyopathy." Oncotarget, vol. 7, no. 24, 2016, pp. 35618-35631.
Qin WD, Liu GL, Wang J, et al. Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy. Oncotarget. 2016;7(24):35618-35631.
Qin, W. D., Liu, G. L., Wang, J., Wang, H., Zhang, J. N., Zhang, F., Ma, Y., Ji, X. Y., Li, C., & Zhang, M. X. (2016). Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy. Oncotarget, 7(24), 35618-35631. https://doi.org/10.18632/oncotarget.8343
Qin WD, et al. Poly(ADP-ribose) Polymerase 1 Inhibition Protects Cardiomyocytes From Inflammation and Apoptosis in Diabetic Cardiomyopathy. Oncotarget. 2016 Jun 14;7(24):35618-35631. PubMed PMID: 27027354.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy. AU - Qin,Wei-Dong, AU - Liu,Guo-Liang, AU - Wang,Juan, AU - Wang,Hao, AU - Zhang,Jian-Ning, AU - Zhang,Fan, AU - Ma,Yang, AU - Ji,Xin-Ying, AU - Li,Chen, AU - Zhang,Ming-Xiang, PY - 2015/09/26/received PY - 2016/03/14/accepted PY - 2016/3/31/pubmed PY - 2018/1/6/medline PY - 2016/3/31/entrez KW - Pathology Section KW - apoptosis KW - diabetic cardiomyopathy KW - hyperglycemia KW - inflammatory response KW - poly(ADP-ribose) polymerase 1 SP - 35618 EP - 35631 JF - Oncotarget JO - Oncotarget VL - 7 IS - 24 N2 - Diabetic cardiomyopathy (DCM) is characterized by structural alterations such as cardiomyocyte hypertrophy, necrosis and focal fibrosis. Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear enzyme which can be activated by DNA damage and plays a critical role in various diseases. We hypothesized that PARP-1 may play an important role in DCM and that its inhibition may protect cardiomyocytes from inflammation and apoptosis in DCM. H9c2 cardiomyocytes were treated with normal glucose, mannitol or high glucose (HG). Male C57BL/6 mice or PARP-1-/- mice were treated with streptozotocin (STZ) by intraperitoneal injection for 5 consecutive days to induce diabetes. In vitro, HG stimulation induced oxidative stress and DNA damage and increased PARP-1 expression and activity. Compared with the control, pretreatment with PARP-1 siRNA signiï¬쎼cantly reduced HG-induced inflammatory response, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6 secretion, and intercellular adhesion molecule-1 (ICAM-1) and inducible nitric oxide synthase (iNOS) expression. PARP-1 inhibition reduced HG-induced cardiomyocyte apoptosis through downregulation of cleaved caspases and activation of IGF-1R/Akt pathway. In vivo, hyperglycemia increased the protein expression of nitrotyrosine and PARP-1 as well as PARP-1 activity. PARP-1 gene deletion significantly improved cardiac dysfunction and reduced inflammatory response and apoptosis. This work demonstrated the critical role of PARP-1 in diabetic heart injury, and suggested that PARP-1 inhibition may be a feasible strategy for the treatment of DCM. SN - 1949-2553 UR - https://www.unboundmedicine.com/medline/citation/27027354/Poly_ADP_ribose__polymerase_1_inhibition_protects_cardiomyocytes_from_inflammation_and_apoptosis_in_diabetic_cardiomyopathy_ L2 - https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.8343 DB - PRIME DP - Unbound Medicine ER -